Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow COGNITION THERAPEUTICS INC

Get SEC filing alerts via email and in your feed for COGNITION THERAPEUTICS INC

CGTX

COGNITION THERAPEUTICS INC

About COGNITION THERAPEUTICS INC

Cognition Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related neurodegenerative diseases such as Alzheimer's disease and Lewy body dementia. Its lead candidate, zervimesine (CT1812), aims to protect neurons by displacing toxic protein oligomers at synapses. The company leverages biomarker-driven clinical trials, strategic collaborations, and proprietary drug libraries to address unmet medical needs in CNS disorders.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from COGNITION THERAPEUTICS INC

1
1
COGNITION THERAPEUTICS INC Cognition Therapeutics Reports $33.97 Million Net Loss for 2024, Concludes Phase 2 MAGNIFY Study

Via official filing (AI summary) | over 1 year ago | 0 comments